Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
depigmented polymerized phleum pratense pollen extract
- Development stage
- Phase 3
- Lead developer
- Leti Pharma
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Subcutaneous, Sublingual
01
Overview
Depigmented polymerized Phleum pratense pollen extract (marketed under the brand name Depigoid Phleum) is an allergen immunotherapy product (allergoid) developed by Laboratorios LETI. The active ingredient is a chemically modified extract of *Phleum pratense* (timothy grass) pollen that has been depigmented to remove low-molecular-weight, non-allergenic components and subsequently polymerized using glutaraldehyde. This modification reduces the extract's IgE-binding capacity (allergenicity) while preserving its T-cell reactivity (immunogenicity), thereby minimizing the risk of IgE-mediated systemic allergic reactions (anaphylaxis) and allowing for rapid up-dosing. The immunotherapy works by inducing immune tolerance, promoting the generation of allergen-specific IgG4 and IgA antibodies, and stimulating regulatory T (Treg) and regulatory B (Breg) cells that secrete anti-inflammatory cytokines like IL-10. It is developed for the treatment of grass pollen-induced allergic rhinoconjunctivitis and asthma, and has been evaluated in clinical trials for both subcutaneous (SCIT) and sublingual (SLIT) administration.
- Brand names
- Depigoid PhleumDepigoid Phleum pratense
- Other names
- depigmented-polymerized Phleum pratense pollen extractdepigmented glutaraldehyde-polymerized Phleum pratense pollen extractDPG-POL-Phl p
02
Targets
Timothy grass-specific IgE (Timothy grass-specific immunoglobulin E)
Beyond the preview
Go deeper on depigmented polymerized phleum pratense pollen extract.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on depigmented polymerized phleum pratense pollen extract.